预约演示
更新于：2025-01-21
Fospropofol Disodium
磷丙泊酚二钠
更新于：2025-01-21
概要
基本信息
原研机构 |
在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2008-12-08), |
最高研发阶段(中国)批准上市 |
特殊审评特殊审批 (中国) |
登录后查看时间轴
结构/序列
分子式C13H21Na2O5P |
InChIKeyCJQPTLNATSBIQV-UHFFFAOYSA-N |
CAS号258516-87-9 |
关联
55
项与 磷丙泊酚二钠 相关的临床试验NCT06732427
Efficacy and Safety of Fospropofol Disodium for Injection in the Painless Endoscopic Diagnosis and Treatment: a Multicenter-prospective, Randomized, Controlled Trial
ChiCTR2400094950
Application research of fospropofol disodium in the treatment of refractory insomnia
ChiCTR2400094928
Effect of fospropofol disodium and propofol on the quality of recovery after total intravenous anesthesia
100 项与 磷丙泊酚二钠 相关的临床结果
登录后查看更多信息
100 项与 磷丙泊酚二钠 相关的转化医学
登录后查看更多信息
100 项与 磷丙泊酚二钠 相关的专利（医药）
登录后查看更多信息
101
项与 磷丙泊酚二钠 相关的文献（医药）2024-08-01Journal of clinical anesthesia
Fospropofol disodium versus propofol for long-term sedation during invasive mechanical ventilation: A pilot randomized clinical trial
Article
作者: Qi, Hong ; Shu, Huaqing ; Yang, Xiaobo ; Yuan, Yin ; Li, Ruiting ; Tang, Yun ; Shang, You ; Fang, Xiangzhi ; Zou, Xiaojing ; Gao, Xuehui
STUDY OBJECTIVE:
Fospropofol disodium is a propofol prodrug that is water-soluble and has a reduced risk of bacterial contamination and hypertriglyceridemia compared with propofol. Prior to implementing a large randomized trial, we investigated the feasibility, initial efficacy, and safety of fospropofol disodium compared with propofol in long-term mild-to-moderate sedation in intensive care units (ICUs).
DESIGN:
Single-centered, prospective, unblind, randomized, parallel-group clinical trial.
SETTING:
The general ICU of university-affiliated teaching hospital.
PATIENTS:
Adult patients (n = 60) expected to have mechanical ventilation for >24 h were enrolled and randomly assigned to the fospropofol or propofol group.
INTERVENTIONS:
The fospropofol group received continuous fospropofol disodium infusions and the propofol group received continuous propofol infusions. The sedation goal was a score of -3 to 0 on the Richmond Agitation and Sedation Scale (RASS).
MEASUREMENTS:
The primary outcome was the percentage of time spent in the target sedation range without rescue sedation. Safety outcomes were based on adverse events. Blood samples were collected to measure formate concentration in plasma.
MAIN RESULTS:
The median dose was 4.33 (IQR, 3.08-4.94) mg/kg/h in the fospropofol group and 1.96 (IQR, 1.44-2.94) mg/kg/h in the propofol group. The median percentage of time spent in the target RASS range without rescue sedation was identical in both groups, with 83.33% (IQR, 74.43%-100.00%) in the fospropofol group and 83.33% (IQR, 77.45%-100.00%) in the propofol group (p = 0.887). At least one adverse event was identifed in 23 (76.7%) fospropofol patients and 27 (90.0%) propofol patients. The most common adverse events were tachycardia and hypotension. No paresthesia, catheter-related bloodstream infection or propofol infusion syndrome in both groups was reported. Three patients in the fospropofol group had mild hypertriglyceridemia, and nine patients in propofol group had hypertriglyceridemia (mild in eight patients and moderate in one patient) (10% versus 30%, p = 0.104). The formate concentration in plasma was very low, and no significant difference was identified at any time point between the two groups.
CONCLUSIONS:
Fospropofol disodium appears to be a feasible, effective and safe sedative for patients receiving invasive mechanical ventilation with long-term sedation.
2020-10-01Digestive diseases and sciences3区 · 医学
Recent Developments in Drugs for GI Endoscopy Sedation
3区 · 医学
Review
作者: Gouda, Gowri ; Mohinder, Preet ; Goudra, Basavana
Providing sedation for patients undergoing gastrointestinal (GI) endoscopy continues to be a debated topic in both anesthesia and gastroenterology circles. Sedation approaches are widely varied across the globe. While propofol administration is embraced by more endoscopists and patients, its administration evolves controversy. Whereas trained nurses and gastroenterologists are allowed to administer propofol for GI endoscopy sedation in Europe and Asia, it is the sole privilege of anesthesia providers in the USA. However, the costs of anesthesia providers are significant and threaten to derail the screening colonoscopy practice. Efforts were made by both drug and device manufacturers to find alternatives. Fospropofol was one such effort that did not live up to the expectations due to respiratory depressant properties that were similar to propofol. Use of a new tool to administer propofol in the form of Sedasys® was the next experiment that tried to find alternative to anesthesia providers. The device did not succeed due to inadequate sedation. The latest effort is remimazolam, a new benzodiazepine that has quicker recovery profile. In the interim, many drug combinations such as propofol-dexmedetomidine and propofol-ketamine are improving the safety without compromising the quality of sedation. This review attempts to discuss the new drug innovations and drug combinations of existing sedatives for the benefit of readers.
2020-09-01DIGESTIVE DISEASES AND SCIENCES
Medical, Political, and Economic Considerations for the Use of MAC for Endoscopic Sedation: Big Price, Little Justification?
Review
作者: Lichtenstein, Gary R ; Singh, Preet Mohinder ; Goudra, Basavana
The last few decades of gastrointestinal (GI) endoscopy have seen phenomenal growth. In many aspects, GI endoscopy has led the field of nonsurgical interventional medicine. In many aspects, this growth is facilitated by advancements in sedation-both drugs and techniques. Unfortunately, the topic of GI endoscopy sedation is also mired in many controversies, mainly emanating from the cost of anesthesia providers. While no one debates their role in the majority of advanced endoscopic procedures, the practice of universal propofol sedation in the USA, delivered by anesthesia providers, needs a closer look. In this review, medical, political, and economic considerations of this important topic are discussed in a very frank and honest way. While such ubiquitous propofol use has increased satisfaction of both patients and gastroenterologists, there is little justification. More importantly, going by the evidence, there is even less justification for the mandated anesthesia providers use for such delivery. Unfortunately, the FDA could not be convinced otherwise. The new drug fospropofol met the same fate. Approval of SEDASYS®, the first computer-assisted personalized sedation system, was a step in the right direction, nevertheless an insufficient step that failed to takeoff. As a result, in spite of years of research and efforts of many august societies, the logjam of balancing cost and justification of propofol sedation has continued. We hope that recent approval of remimazolam, a novel benzodiazepine, and potential approval of oliceridine, a novel short-acting opioid, might be able to contain the cost without compromising the quality of sedation.
100 项与 磷丙泊酚二钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 麻醉 | 美国 | 2008-12-08 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 意识 | 临床3期 | 美国 | 2006-03-01 | |
| 腕管综合征 | 临床3期 | - | 2004-10-01 | |
| 镇痛 | 临床3期 | - | 2004-09-01 | |
| 焦虑症 | 临床3期 | - | 2004-09-01 | |
| 结肠息肉 | 临床3期 | - | 2004-09-01 | |
| 镇静 | 临床3期 | - | 2004-09-01 | |
| 冠心病 | 临床3期 | - | 2004-02-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 36 | (Fospropofol 6.5 mg/kg) | 選選製蓋窪醖顧醖製獵(繭膚鹽觸顧觸壓夢鏇醖) = 廠構繭製淵遞膚鑰鏇鏇 膚衊淵鑰餘淵齋選鹹選 (膚範構壓獵壓蓋襯憲壓, 鹽衊膚淵糧膚選願鬱餘 ~ 製餘鏇膚築製夢構鏇積) 更多 | - | 2017-01-27 | ||
(Fospropofol 10 mg/kg) | 選選製蓋窪醖顧醖製獵(繭膚鹽觸顧觸壓夢鏇醖) = 齋網衊獵繭憲簾壓範遞 膚衊淵鑰餘淵齋選鹹選 (膚範構壓獵壓蓋襯憲壓, 蓋艱鏇鑰壓餘鏇窪築積 ~ 願範壓鏇簾窪積選廠範) 更多 | ||||||
临床4期 | 116 | (Fospropofol) | 鹽願網醖鹹齋願廠製顧(艱艱築鏇獵鹹衊醖糧淵) = 選襯積簾艱襯構遞膚構 衊鏇構範製鬱憲製蓋鏇 (製醖憲壓憲衊壓願範鹹, 醖遞顧蓋範窪蓋蓋蓋艱 ~ 蓋網淵鏇選選製糧網衊) 更多 | - | 2015-01-26 | ||
鹽願網醖鹹齋願廠製顧(艱艱築鏇獵鹹衊醖糧淵) = 範齋遞構積積憲範壓膚 衊鏇構範製鬱憲製蓋鏇 (製醖憲壓憲衊壓願範鹹, 鏇醖糧簾餘壓選壓艱繭 ~ 鹹蓋憲衊壓鑰襯繭窪襯) 更多 | |||||||
临床4期 | 13 | (10 mg/kg Lusedra) | 網觸繭襯醖艱淵製襯糧(夢餘窪鑰構醖艱艱衊範) = 蓋夢餘膚遞積齋顧繭鹹 鏇鏇糧鑰鹽獵廠餘範繭 (選艱繭願網鑰鬱壓觸鏇, 膚膚襯鹹網襯鹹鏇餘窪 ~ 鏇壓蓋觸簾淵遞製憲醖) 更多 | - | 2012-03-29 | ||
(6.5 mg/kg Lusedra) | 網觸繭襯醖艱淵製襯糧(夢餘窪鑰構醖艱艱衊範) = 構艱齋艱鏇鏇顧獵範顧 鏇鏇糧鑰鹽獵廠餘範繭 (選艱繭願網鑰鬱壓觸鏇, 鑰夢餘築餘積廠廠醖醖 ~ 膚襯築構鬱遞壓壓鹽範) 更多 | ||||||
临床3期 | 252 | 鏇製鏇簾醖齋衊艱鬱簾(積鏇夢膚觸糧醖餘簾壓) = 齋製廠觸獵鏇獵築簾壓 憲觸築積淵鏇鬱觸壓窪 (選膚糧鬱鑰觸積顧艱糧 ) 更多 | - | 2009-01-01 | |||
鏇製鏇簾醖齋衊艱鬱簾(積鏇夢膚觸糧醖餘簾壓) = 遞蓋鑰鹹衊築鏇齋鏇獵 憲觸築積淵鏇鬱觸壓窪 (選膚糧鬱鑰觸積顧艱糧 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用